Illustrative sHTG Patient Profiles | TRYNGOLZA® (olezarsen)

Representative patient profiles in sHTG

Illustrative patient profiles based on typical clinical presentations in severe hypertriglyceridemia (sHTG).

Oliver, Age 49

TGs >500 mg/dL and diabetes

Fasting triglyceride (TG) levels (3 panels, 6 weeks apart)	672 mg/dL 774 mg/dL 576 mg/dL
BMI	29
Cardiovascular health	Blood pressure: 132/80 mmHg CV history: no prior MI, stroke, or PAD Total cholesterol: 224 mg/dL High-density lipoprotein cholesterol (HDL-C): 40 mg/dL Low-density lipoprotein cholesterol (LDL-C): 66 mg/dL Non–HDL-C: 184 mg/dL
Medical history	Type 2 diabetes mellitus
Current treatment regimen	Omega-3 fatty acid, statin, and fibrate (8 years) Metformin to help manage type 2 diabetes (8 years) GLP-1 to help manage type 2 diabetes (1 year)

These are hypothetical profiles, and medical providers should make their own independent decisions regarding the treatment decisions for their patients.

BMI=body mass index; CV=cardiovascular; GLP-1=glucagon-like peptide-1; MI=myocardial infarction; PAD=peripheral arterial disease.

Oliver's doctor added TRYNGOLZA 50 mg to his current treatment regimen.

After 6 months, his fasting TGs were reduced 49% to 294 mg/dL.

No adverse reactions reported to date.

^{Hypothetical patient case; actor portrayal.}

Evelyn, Age 59

TGs >500 mg/dL and prior AP

Fasting triglyceride (TG) levels (3 panels, 5 weeks apart)	672 mg/dL 734 mg/dL 508 mg/dL
BMI	31
Cardiovascular health	Blood pressure: 134/82 mmHg CV history: no prior MI, stroke, or PAD Total cholesterol: 224 mg/dL High-density lipoprotein cholesterol (HDL-C): 38 mg/dL Low-density lipoprotein cholesterol (LDL-C): 68 mg/dL Non–HDL-C: 176 mg/dL
Medical history	Acute pancreatitis episode 3 years earlier
Current treatment regimen	Has been on omega-3 fatty acid and fibrate for 3 years; HCP prescribes a statin following the 3 most recent lipid panels (on statin for 18 months)

These are hypothetical profiles, and medical providers should make their own independent decisions regarding the treatment decisions for their patients.

AP=acute pancreatitis; BMI=body mass index; CV=cardiovascular; HCP=healthcare provider; MI=myocardial infarction; PAD=peripheral arterial disease.

Evelyn's doctor initiated TRYNGOLZA at 50 mg. After 3 months, her doctor increased to 80 mg for additional TG reduction.

After 6 months on 80 mg, her fasting TGs were reduced 72% to 142 mg/dL, supporting her treatment goal of reducing risk of AP.

Mild injection-site reactions reported.

^{Hypothetical patient case; actor portrayal.}

Christopher, Age 53

TGs >880 mg/dL

Fasting triglyceride (TG) levels (3 panels, 4 weeks apart)	1014 mg/dL 892 mg/dL 939 mg/dL
BMI	34
Cardiovascular health	Blood pressure: 138/85 mmHg CV history: no prior MI, stroke, or PAD Total cholesterol: 277 mg/dL High-density lipoprotein cholesterol (HDL-C): 32 mg/dL Low-density lipoprotein cholesterol (LDL-C): 65 mg/dL (directly measured) Non–HDL-C: 245 mg/dL
Medical history	No acute pancreatitis to date
Current treatment regimen	On TRYNGOLZA 50 mg for 3 months; omega-3 fatty acid and statin for 2 years; HCP prescribes a fibrate; however, triglycerides remain >880 mg/dL upon follow-up 6 weeks later

These are hypothetical profiles, and medical providers should make their own independent decisions regarding the treatment decisions for their patients.

BMI=body mass index; CV=cardiovascular; HCP=healthcare provider; MI=myocardial infarction; PAD=peripheral arterial disease.

Christopher's doctor increased his current dose of TRYNGOLZA to 80 mg to achieve further triglyceride reductions.

After 6 months, Christopher’s fasting TGs were reduced 64% to 339 mg/dL.

No adverse reactions reported to date.

^{Hypothetical patient case; actor portrayal.}

Sheri, Age 35

TGs persistently >880 mg/dL

Fasting triglyceride (TG) levels (3 panels, 2 weeks apart)	1089 mg/dL 1334 mg/dL 1501 mg/dL
BMI	22
Cardiovascular health	Blood pressure: 128/76 mmHg Total cholesterol: 225 mg/dL High-density lipoprotein cholesterol (HDL-C): 35 mg/dL Low-density lipoprotein cholesterol (LDL-C): 70 mg/dL Non–HDL-C: 190 mg/dL
Medical history	Recurrent AP Lethargy and brain fog
Current treatment regimen	Omega-3 fatty acid and fibrate

These are hypothetical profiles, and medical providers should make their own independent decisions regarding the treatment decisions for their patients.
BMI=body mass index; CV=cardiovascular; GLP-1=glucagon-like peptide-1; MI=myocardial infarction; PAD=peripheral arterial disease.

Her doctor initiated TRYNGOLZA 80 mg to maximize TG lowering and reduce Sheri’s risk of acute pancreatitis.

After 6 months, her fasting TGs were reduced 67.5% to 488 mg/dL.

Hypothetical patient case; actor portrayal.

Next Diagnosing FCS

sHTG Results | Patient Profiles

Representative patient profiles in sHTG

TGs >500 mg/dL and diabetes

TGs >500 mg/dL and prior AP

TGs >880 mg/dL

TGs persistently >880 mg/dL

IMPORTANT SAFETY INFORMATION & INDICATIONS

CONTRAINDICATIONS

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Liver Enzyme Abnormalities

ADVERSE REACTIONS

INDICATIONS

Please see full Prescribing Information for TRYNGOLZA.